Burcon NutraScience Past Earnings Performance
Past criteria checks 0/6
Burcon NutraScience's earnings have been declining at an average annual rate of -41.5%, while the Chemicals industry saw earnings growing at 24.9% annually. Revenues have been growing at an average rate of 40.5% per year.
Key information
-41.5%
Earnings growth rate
-22.7%
EPS growth rate
| Chemicals Industry Growth | 4.5% |
| Revenue growth rate | 40.5% |
| Return on equity | -258.6% |
| Net Margin | -3,909.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Burcon NutraScience (TSE:BU) Is In A Good Position To Deliver On Growth Plans
May 19
What Does Burcon NutraScience Corporation's (TSE:BU) Share Price Indicate?
Mar 08We Think Burcon NutraScience (TSE:BU) Can Afford To Drive Business Growth
Dec 24The Compensation For Burcon NutraScience Corporation's (TSE:BU) CEO Looks Deserved And Here's Why
Sep 09Calculating The Fair Value Of Burcon NutraScience Corporation (TSE:BU)
Jul 03Revenue & Expenses BreakdownBeta
How Burcon NutraScience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -7 | 4 | 4 |
| 30 Sep 23 | 0 | -21 | 4 | 4 |
| 30 Jun 23 | 0 | -23 | 4 | 4 |
| 31 Mar 23 | 0 | -25 | 4 | 4 |
| 31 Dec 22 | 0 | -28 | 4 | 5 |
| 30 Sep 22 | 0 | -13 | 4 | 5 |
| 30 Jun 22 | 0 | -11 | 4 | 4 |
| 31 Mar 22 | 0 | -10 | 5 | 3 |
| 31 Dec 21 | 0 | -9 | 5 | 1 |
| 30 Sep 21 | 0 | -8 | 4 | 1 |
| 30 Jun 21 | 0 | -2 | 4 | 1 |
| 31 Mar 21 | 0 | -1 | 4 | 1 |
| 31 Dec 20 | 0 | 0 | 3 | 0 |
| 30 Sep 20 | 0 | 0 | 3 | 0 |
| 30 Jun 20 | 0 | -5 | 2 | 0 |
| 31 Mar 20 | 0 | -5 | 2 | 1 |
| 31 Dec 19 | 0 | -4 | 2 | 1 |
| 30 Sep 19 | 0 | -4 | 2 | 1 |
| 30 Jun 19 | 0 | -5 | 2 | 2 |
| 31 Mar 19 | 0 | -5 | 2 | 2 |
| 31 Dec 18 | 0 | -5 | 2 | 2 |
| 30 Sep 18 | 0 | -5 | 2 | 2 |
| 30 Jun 18 | 0 | -5 | 2 | 2 |
| 31 Mar 18 | 0 | -6 | 2 | 2 |
| 31 Dec 17 | 0 | -6 | 2 | 2 |
| 30 Sep 17 | 0 | -5 | 2 | 2 |
| 30 Jun 17 | 0 | -6 | 2 | 2 |
| 31 Mar 17 | 0 | -6 | 2 | 2 |
| 31 Dec 16 | 0 | -6 | 3 | 2 |
| 30 Sep 16 | 0 | -6 | 2 | 2 |
| 30 Jun 16 | 0 | -6 | 3 | 2 |
| 31 Mar 16 | 0 | -7 | 3 | 3 |
| 31 Dec 15 | 0 | -6 | 3 | 3 |
| 30 Sep 15 | 0 | -7 | 4 | 3 |
| 30 Jun 15 | 0 | -7 | 4 | 3 |
| 31 Mar 15 | 0 | -7 | 3 | 2 |
| 31 Dec 14 | 0 | -6 | 4 | 2 |
| 30 Sep 14 | 0 | -6 | 4 | 2 |
| 30 Jun 14 | 0 | -6 | 4 | 2 |
| 31 Mar 14 | 0 | -6 | 4 | 2 |
| 31 Dec 13 | 0 | -6 | 4 | 2 |
| 30 Sep 13 | 0 | -6 | 4 | 2 |
| 30 Jun 13 | 0 | -6 | 4 | 2 |
Quality Earnings: BU is currently unprofitable.
Growing Profit Margin: BU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BU is unprofitable, and losses have increased over the past 5 years at a rate of 41.5% per year.
Accelerating Growth: Unable to compare BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BU is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-53.6%).
Return on Equity
High ROE: BU has a negative Return on Equity (-258.6%), as it is currently unprofitable.